Brokerages expect Cardiovascular Systems, Inc. (NASDAQ:CSII) to post sales of $53.25 million for the current quarter, according to Zacks. Three analysts have issued estimates for Cardiovascular Systems’ earnings. The lowest sales estimate is $52.90 million and the highest is $53.80 million. Cardiovascular Systems posted sales of $50.04 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 6.4%. The company is scheduled to issue its next earnings report on Wednesday, January 24th.

According to Zacks, analysts expect that Cardiovascular Systems will report full-year sales of $53.25 million for the current financial year, with estimates ranging from $224.94 million to $226.20 million. For the next fiscal year, analysts expect that the firm will post sales of $254.47 million per share, with estimates ranging from $250.81 million to $260.60 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that cover Cardiovascular Systems.

Cardiovascular Systems (NASDAQ:CSII) last posted its quarterly earnings results on Wednesday, October 25th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. Cardiovascular Systems had a positive return on equity of 0.74% and a negative net margin of 0.93%. The business had revenue of $49.70 million for the quarter, compared to the consensus estimate of $51.00 million. During the same quarter in the prior year, the company earned ($0.06) EPS. The business’s revenue was down .2% compared to the same quarter last year.

A number of equities analysts have recently issued reports on CSII shares. Citigroup Inc. started coverage on Cardiovascular Systems in a research report on Thursday, September 21st. They set a “market perform” rating on the stock. Needham & Company LLC reissued a “buy” rating and set a $37.00 price target on shares of Cardiovascular Systems in a research report on Thursday, October 12th. Zacks Investment Research downgraded Cardiovascular Systems from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Raymond James Financial, Inc. started coverage on Cardiovascular Systems in a research report on Friday, September 22nd. They set a “market perform” rating on the stock. Finally, BidaskClub downgraded Cardiovascular Systems from a “sell” rating to a “strong sell” rating in a research report on Friday, August 18th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. Cardiovascular Systems presently has a consensus rating of “Hold” and a consensus price target of $38.00.

Cardiovascular Systems (CSII) opened at $24.62 on Tuesday. Cardiovascular Systems has a 12-month low of $23.00 and a 12-month high of $33.11. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.83 and a current ratio of 4.30. The stock has a market capitalization of $806.62, a price-to-earnings ratio of 1,219.00 and a beta of 2.53.

COPYRIGHT VIOLATION WARNING: “Zacks: Analysts Anticipate Cardiovascular Systems, Inc. (CSII) Will Post Quarterly Sales of $53.25 Million” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/11/21/zacks-analysts-anticipate-cardiovascular-systems-inc-csii-will-post-quarterly-sales-of-53-25-million.html.

In other Cardiovascular Systems news, Director Edward M. Brown sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $29.16, for a total value of $583,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Brown sold 13,031 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $29.09, for a total value of $379,071.79. The disclosure for this sale can be found here. 3.30% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC raised its stake in shares of Cardiovascular Systems by 22.7% in the second quarter. Jennison Associates LLC now owns 12,567 shares of the medical device company’s stock worth $405,000 after purchasing an additional 2,323 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Cardiovascular Systems by 26.6% in the first quarter. Parametric Portfolio Associates LLC now owns 33,672 shares of the medical device company’s stock worth $952,000 after purchasing an additional 7,072 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Cardiovascular Systems by 12.6% in the second quarter. Vanguard Group Inc. now owns 1,864,604 shares of the medical device company’s stock worth $60,096,000 after purchasing an additional 208,248 shares during the last quarter. Timpani Capital Management LLC raised its stake in shares of Cardiovascular Systems by 24.2% in the second quarter. Timpani Capital Management LLC now owns 116,397 shares of the medical device company’s stock worth $3,751,000 after purchasing an additional 22,649 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Cardiovascular Systems by 53.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 200,312 shares of the medical device company’s stock worth $5,664,000 after purchasing an additional 69,659 shares during the last quarter. 75.54% of the stock is owned by institutional investors and hedge funds.

Cardiovascular Systems Company Profile

Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.

Get a free copy of the Zacks research report on Cardiovascular Systems (CSII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardiovascular Systems (NASDAQ:CSII)

Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.